Overview

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

Status:
Completed

Trial end date:
2021-01-14

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy and safety of Upadacitinib compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis (UC).

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Upadacitinib